Related Experiment Video
Updated: Aug 18, 2026
Isolation and Characterization of Primary Rat Valve Interstitial Cells: A New Model to Study Aortic Valve Calcification
Published on: November 20, 2017
Valve endothelial monolayer fissuring via RhoA activity induces 3D calcific aortic valve lesion emergence as revealed
Insights
Calcific aortic valve disease (CAVD) research reveals early biomarkers like endothelial fissuring. Targeting RhoA activation with ROCK inhibitors may prevent lesion formation, offering new therapeutic avenues.
Area of Science:
- Cardiovascular Biology
- Biomaterials Science
- Medical Imaging
Background:
- Calcific aortic valve disease (CAVD) is a prevalent degenerative condition in aging populations with poor prognosis and no effective pharmacological treatments.
- Current treatments for CAVD are often initiated at irreversible, end-stage disease phases.
- Early identification of CAVD biomarkers and therapeutic targets is crucial for timely intervention.
Purpose of the Study:
- To establish a novel multimodal in-vitro platform for live-tracing calcific lesion emergence in CAVD.
- To unravel transitional cellular and matrix events during the onset of calcific lesion formation.
- To identify and evaluate potential therapeutic targets for early-stage CAVD.
Main Methods:
- Development of a 3D in-vitro CAVD model using lineage-traced VEC and VIC cells.
- Integration of live optical coherence and fluorescence microscopy for longitudinal imaging.
- Pharmacological inhibition of RhoA and Rac1 pathways to assess their role in CAVD progression.
Main Results:
- Identified endothelial monolayer fissuring and adjacent aggregate formation as key biomarkers for CAVD onset.
- Observed dense VIC and ECM conglomerates beneath endothelial aggregates, indicating pathogenic progression.
- Demonstrated that RhoA activation is involved in CAVD, and its inhibition via ROCK prevents key pathological features like endothelial delamination and lesion formation.
Conclusions:
- The established live-imaging platform enables real-time identification of CAVD onset biomarkers.
- RhoA signaling, specifically through ROCK, is a critical target for preventing CAVD progression.
- This research provides a foundation for discovering novel therapeutic strategies for early-stage CAVD.
Abstract:
Calcific aortic valve disease (CAVD) is a degenerative disease with wide prevalence in the aging population and a low survival rate after onset of symptoms, yet there are no effective pharmacological treatments. Many patients present to the clinic with symptoms at end-stages of CAVD, when the disease may be irreversible. The ability to identify and live-trace calcific lesion emergence in-vivo would allow for the identification of disease biomarkers and discovery of therapeutic targets at earlier, more treatable stages. In this work, we establish a new multimodal in-vitro CAVD platform consisting of lineage traced-VEC and VIC cells in a 3D model combined with live optical coherence and fluorescence microscopy to unravel VEC, VIC, and matrix transitional events during calcific lesion formation. We discover that fissuring of the endothelial monolayer combined with the formation of dense aggregates in adjacent regions is a key biomarker of the onset of lesion formation. This coincides with the formation of dense VIC and ECM conglomerates under endothelial aggregates, an additional biomarker of pathogenesis. Further, we discover that fibrotic tissue compaction is correlated with but not necessary for lesion formation. Additionally, we identify RhoA activation in disease-treated samples. We demonstrate that RhoA inhibition through ROCK, but not Rac1 inhibition, prevents delamination of the endothelial monolayer, fibrotic remodeling, and emergence of calcific lesions. Together, this work establishes a new longitudinal live-imaging platform that identifies emergent cell and matrix biological signatures of CAVD onset and enables the evaluation of therapeutic interventions.
